| Trial ID: | L0174 |
| Source ID: | NCT00529204
|
| Associated Drug: |
Exenatide
|
| Title: |
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Terminated
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT00529204/results
|
| Conditions: |
Diabetes Complications|Fatty Liver
|
| Interventions: |
Drug: exenatide
|
| Outcome Measures: |
Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy|Changes in Components of Liver Histology at Baseline and Week 24 Including Steatosis, Inflammation and Fibrosis|Safety of Exenatide in Patients With NAFLD and Type 2 Diabetes
|
| Sponsor/Collaborators: |
University of California, Davis|Amylin Pharmaceuticals, LLC.|Eli Lilly and Company
|
| Gender: |
All
|
| Age: |
18 Years to 70 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
1
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
|
| Start Date: |
October 2007
|
| Completion Date: |
February 2010
|
| Results First Posted: |
December 22, 2014
|
| Last Update Posted: |
June 20, 2017
|
| Locations: |
University of California Davis Medical Center, Sacramento, California, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT00529204
|
